Literature DB >> 27391806

Human chorionic gonadotropin detection in cerebrospinal fluid of patients with a germinoma and its prognostic significance: assessment by using a highly sensitive enzyme immunoassay.

Kohei Fukuoka1, Takaaki Yanagisawa1, Tomonari Suzuki1, Mitsuaki Shirahata2, Jun-Ichi Adachi2, Kazuhiko Mishima2, Takamitsu Fujimaki3, Hideki Katakami4, Masao Matsutani2, Ryo Nishikawa2.   

Abstract

OBJECTIVE Human chorionic gonadotropin (HCG) can be detected in a certain population of patients with a germinoma, but the frequency of germinoma HCG secretion and the prognostic value of HCG in the CSF are unknown. METHODS The authors measured HCG levels in sera and CSF in patients with a histologically confirmed germinoma by using a highly sensitive assay known as an immune complex transfer enzyme immunoassay (EIA), which is more than 100 times as sensitive as the conventional method, and they analyzed the correlation between HCG levels and the prognoses of patients with a germinoma. RESULTS HCG levels in sera and CSF of 35 patients with a germinoma were examined with the immune complex transfer EIA. The median CSF HCG levels in patients with a germinoma during the pretreatment and posttreatment evaluations were 192.5 pg/ml (range 1.2-13,116.5 pg/ml) and 18.7 pg/ml (1.2-283.9 pg/ml), respectively. Before treatment, the CSF HCG level was greater than the cutoff value in 85.7% of the patients with a germinoma. The authors compared survival rates among the patients by using a CSF HCG cutoff level of 1000 pg/ml, and the difference was statistically significant between the groups (p = 0.029, log-rank test). CONCLUSIONS Results of this study demonstrate that most germinomas secrete HCG. Patients with a germinoma that secretes higher amounts of HCG in their CSF experienced recurrence more frequently than those with lower CSF HCG levels.

Entities:  

Keywords:  AFP = alpha-fetoprotein; CARE = carboplatin and etoposide; CR = complete response; EIA = enzyme immunoassay; GCT = germ cell tumor; HCG = human chorionic gonadotropin; ICT = immune complex transfer; NGGCT = nongerminomatous GCT; germinoma; human chorionic gonadotropin; oncology; prognosis

Mesh:

Substances:

Year:  2016        PMID: 27391806     DOI: 10.3171/2016.4.PEDS1658

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  7 in total

1.  Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium.

Authors:  Hirokazu Takami; Kohei Fukuoka; Shintaro Fukushima; Taishi Nakamura; Akitake Mukasa; Nobuhito Saito; Takaaki Yanagisawa; Hideo Nakamura; Kazuhiko Sugiyama; Masayuki Kanamori; Teiji Tominaga; Taketoshi Maehara; Mitsutoshi Nakada; Yonehiro Kanemura; Akio Asai; Hideo Takeshima; Yuichi Hirose; Toshihiko Iuchi; Motoo Nagane; Koji Yoshimoto; Akira Matsumura; Kazuhiko Kurozumi; Hiroyuki Nakase; Keiichi Sakai; Tsutomu Tokuyama; Soichiro Shibui; Yoichi Nakazato; Yoshitaka Narita; Ryo Nishikawa; Masao Matsutani; Koichi Ichimura
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

2.  Significance of human chorionic gonadotropin as a predictor of resistance to standard chemo-radiotherapy for pure germinoma.

Authors:  Akihiro Inoue; Takanori Ohnishi; Shohei Kohno; Shiro Ohue; Shinji Iwata; Shirabe Matsumoto; Masahiro Nishikawa; Saya Ozaki; Yawara Nakamura; Yosuke Mizuno; Riko Kitazawa; Takeharu Kunieda
Journal:  Neurosurg Rev       Date:  2017-08-18       Impact factor: 3.042

3.  Roles of Tumor Markers in Central Nervous System Germ Cell Tumors Revisited with Histopathology-Proven Cases in a Large International Cohort.

Authors:  Hirokazu Takami; Christopher S Graffeo; Avital Perry; Caterina Giannini; Yoichi Nakazato; Nobuhito Saito; Masao Matsutani; Ryo Nishikawa; Koichi Ichimura; David J Daniels
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

Review 4.  Advances in Molecular Profiling and Developing Clinical Trials of CNS Germ Cell Tumors: Present and Future Directions.

Authors:  Hirokazu Takami
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

5.  Low tumor cell content predicts favorable prognosis in germinoma patients.

Authors:  Hirokazu Takami; Kaishi Satomi; Kohei Fukuoka; Shintaro Fukushima; Yuko Matsushita; Kai Yamasaki; Taishi Nakamura; Shota Tanaka; Akitake Mukasa; Nobuhito Saito; Tomonari Suzuki; Takaaki Yanagisawa; Hideo Nakamura; Kazuhiko Sugiyama; Kaoru Tamura; Taketoshi Maehara; Mitsutoshi Nakada; Masahiro Nonaka; Akio Asai; Kiyotaka Yokogami; Hideo Takeshima; Toshihiko Iuchi; Yonehiro Kanemura; Keiichi Kobayashi; Motoo Nagane; Kazuhiko Kurozumi; Koji Yoshimoto; Masahide Matsuda; Akira Matsumura; Yuichi Hirose; Tsutomu Tokuyama; Toshihiro Kumabe; Yoshitaka Narita; Soichiro Shibui; Yoichi Nakazato; Ryo Nishikawa; Masao Matsutani; Koichi Ichimura
Journal:  Neurooncol Adv       Date:  2021-08-10

Review 6.  Biomarkers for risk-based treatment modifications for CNS germ cell tumors: Updates on biological underpinnings, clinical trials, and future directions.

Authors:  Hirokazu Takami; Koichi Ichimura
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

7.  Case report: Fluctuating tumor markers in a boy with gonadotropin-releasing hormone-independent precocious puberty induced by a pineal germ cell tumor.

Authors:  Alessandro Cattoni; Assunta Albanese
Journal:  Front Pediatr       Date:  2022-08-23       Impact factor: 3.569

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.